Delonix Bioworks Ltd. Comprising experts in synthetic biology, vaccinology, and cancer immunotherapies, Delonix strives to revolutionize the development and manufacture of medicines for challenging health issues. Their core focus lies in the design and engineering of microbial strains, both for manufacturing purposes and as medicines to combat infectious diseases, cancer, and more.

Inspired by nature, Delonix harnesses the potential of adjuvant molecules, polysaccharide protein conjugates, and diverse antigens, refining and biosynthesizing them efficiently within cells. This scientific approach simplifies processes while fostering product innovation. Delonix also pioneers synthetic vaccines by ingeniously engineering bacteria to act as live vaccine vectors, transforming pathogens into protective agents against stubborn bacterial infections.

In the realm of synthetic cancer therapies, Delonix utilizes bacteria's ability to induce tumor cell lysis and immune stimulation. By employing synthetic biology techniques, they redesign bacteria to target solid tumors and continuously deliver a range of therapeutic payloads. With cutting-edge platforms for synthetic biology and vaccine technology, Delonix offers complete toolkits for engineering non-model microbes, data-driven rational design, high throughput, and automation.

Their expertise in surfomics, reverse vaccinology, and immune checkpoints aids in efficient antigen discovery and vaccine development. Delonix's groundbreaking work has earned recognition, including winning Boehringer Ingelheim's Innovation Prize in 2020. Their commitment to transforming healthcare is evident in their recent series seed financing of $14 million to accelerate the development of innovative synthetic vaccines.

Headquartered in Shanghai, China, Delonix Bioworks Ltd